Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Primary Progressive Multiple Sclerosis (PPMS)-Pipeline Review, H2 2016

Primary Progressive Multiple Sclerosis (PPMS)-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Primary Progressive Multiple Sclerosis (PPMS)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Primary Progressive Multiple Sclerosis (PPMS)-Pipeline Review, H2 2016', provides an overview of the Primary Progressive Multiple Sclerosis (PPMS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Progressive Multiple Sclerosis (PPMS) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Primary Progressive Multiple Sclerosis (PPMS)

The report reviews pipeline therapeutics for Primary Progressive Multiple Sclerosis (PPMS) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Primary Progressive Multiple Sclerosis (PPMS) therapeutics and enlists all their major and minor projects

The report assesses Primary Progressive Multiple Sclerosis (PPMS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Primary Progressive Multiple Sclerosis (PPMS)

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Primary Progressive Multiple Sclerosis (PPMS) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Primary Progressive Multiple Sclerosis (PPMS) Overview 7

Therapeutics Development 8

Pipeline Products for Primary Progressive Multiple Sclerosis (PPMS)-Overview 8

Primary Progressive Multiple Sclerosis (PPMS)-Therapeutics under Development by Companies 9

Primary Progressive Multiple Sclerosis (PPMS)-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Primary Progressive Multiple Sclerosis (PPMS)-Products under Development by Companies 13

Primary Progressive Multiple Sclerosis (PPMS)-Companies Involved in Therapeutics Development 14

F. Hoffmann-La Roche Ltd. 15

Genzyme Corporation 16

Glialogix, Inc. 17

Kyorin Pharmaceutical Co., Ltd. 18

MedDay SA 19

Santhera Pharmaceuticals Holding AG 20

Teva Pharmaceutical Industries Ltd. 21

Primary Progressive Multiple Sclerosis (PPMS)-Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 31

biotin-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

GLX-1112-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

GZ-402668-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

IB-MS-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

ibudilast-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

idebenone-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

laquinimod sodium-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

masitinib-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

ocrelizumab-Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

Small Molecules for Primary Progressive Multiple Sclerosis and Secondary Progressive Multiple Scleros-Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

Stem Cell Therapy for CNS Disorders-Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Primary Progressive Multiple Sclerosis (PPMS)-Dormant Projects 83

Primary Progressive Multiple Sclerosis (PPMS)-Discontinued Products 84

Primary Progressive Multiple Sclerosis (PPMS)-Product Development Milestones 85

Featured News & Press Releases 85

Jul 13, 2016: MediciNova Announces Initiation of Interim Efficacy Analysis in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS 85

Jun 28, 2016: Roche's marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA 86

May 25, 2016: MedDay attends European Academy of Neurology 2016 and presents extension phase results of the MS-SPI trial 87

Apr 21, 2016: MedDay reports full data from pivotal Phase IIb/III MS-SPI / MS-ON studies with MD1003 in Multiple Sclerosis at AAN 87

Mar 22, 2016: FDA Grants Fast Track Designation for MediciNovas MN-166 (ibudilast) for Progressive Multiple Sclerosis 89

Feb 17, 2016: FDA Grants Breakthrough Therapy Designation for Genentech's Investigational Medicine Ocrelizumab in Primary Progressive Multiple Sclerosis 89

Dec 01, 2015: MedDay provides update on MS-ON study of MD-1003 90

Oct 20, 2015: Clinical trial shows first ever positive results in treating primary progressive and relapsing multiple sclerosis 92

Oct 10, 2015: More Results Released from Positive Phase III Clinical Trial of Ocrelizumab in Primary Progressive MS 93

Apr 23, 2015: Teva and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive MS 94

Mar 04, 2015: MedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting 94

Feb 01, 2015: MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at AAN 67th Annual Meeting in Washington, DC 95

Appendix 96

Methodology 96

Coverage 96

Secondary Research 96

Primary Research 96

Expert Panel Validation 96

Contact Us 96

Disclaimer 97

List of Figures

Number of Products under Development for Primary Progressive Multiple Sclerosis (PPMS), H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Top 10 Targets, H2 2016 23

Number of Products by Stage and Top 10 Targets, H2 2016 23

Number of Products by Top 10 Mechanism of Actions, H2 2016 25

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 25

Number of Products by Routes of Administration, H2 2016 27

Number of Products by Stage and Routes of Administration, H2 2016 27

Number of Products by Molecule Types, H2 2016 29

Number of Products by Stage and Molecule Types, H2 2016 29

List of Tables

Number of Products under Development for Primary Progressive Multiple Sclerosis (PPMS), H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Primary Progressive Multiple Sclerosis (PPMS)-Pipeline by AB Science SA, H2 2016 14

Primary Progressive Multiple Sclerosis (PPMS)-Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 15

Primary Progressive Multiple Sclerosis (PPMS)-Pipeline by Genzyme Corporation, H2 2016 16

Primary Progressive Multiple Sclerosis (PPMS)-Pipeline by Glialogix, Inc., H2 2016 17

Primary Progressive Multiple Sclerosis (PPMS)-Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 18

Primary Progressive Multiple Sclerosis (PPMS)-Pipeline by MedDay SA, H2 2016 19

Primary Progressive Multiple Sclerosis (PPMS)-Pipeline by Santhera Pharmaceuticals Holding AG, H2 2016 20

Primary Progressive Multiple Sclerosis (PPMS)-Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 21

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Stage and Target, H2 2016 24

Number of Products by Stage and Mechanism of Action, H2 2016 26

Number of Products by Stage and Route of Administration, H2 2016 28

Number of Products by Stage and Molecule Type, H2 2016 30

Primary Progressive Multiple Sclerosis (PPMS)-Dormant Projects, H2 2016 83

Primary Progressive Multiple Sclerosis (PPMS)-Discontinued Products, H2 2016 84

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

F. Hoffmann-La Roche Ltd.

Genzyme Corporation

Glialogix, Inc.

Kyorin Pharmaceutical Co., Ltd.

MedDay SA

Santhera Pharmaceuticals Holding AG

Teva Pharmaceutical Industries Ltd.

Primary Progressive Multiple Sclerosis (PPMS) Therapeutic Products under Development, Key Players in Primary Progressive Multiple Sclerosis (PPMS) Therapeutics, Primary Progressive Multiple Sclerosis (PPMS) Pipeline Overview, Primary Progressive Multiple Sclerosis (PPMS) Pipeline, Primary Progressive Multiple Sclerosis (PPMS) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com